Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aimovig

Teva Pharma logo

Teva buys into Heptares oral CGRP programme for migraine

Signs$410m alliance for early-stage candidates in potentially-lucrative drug class

Eli Lilly HQ

Third positive phase III trial for Lilly/Incyte’s baricitinib

Baricitinib beats methotrexate in rheumatoid arthritis

Teva Pharma logo

Teva rolls out first migraine patch in US

Delivers alternative treatment option for migraine sufferers

Teva Pharma logo

Teva says chronic migraine drug is ready for phase III

TEV-48125 efficacy “has not previously been achieved”

- PMLiVE

Cyramza gets FDA green light in lung cancer

Drug steadily being approved for further uses

Eli Lilly HQ

Lilly launches GLP-1 agonist Trulicity in US

Once-weekly treatment will challenge GSK's Tanzeum, AZ's Bydureon and Novo's Victoza in diabetes

- PMLiVE

AZ and Lilly set up BACE camp for Alzheimer’s

Lilly will pay AZ up to $500m in development and regulatory costs

- PMLiVE

FDA approves migraine headband

STX-Med’s electronic Cefaly device offers drug-free treatment option

- PMLiVE

Lilly agrees two antibody deals

Signs agreements with Genmab and Arteaus Therapeutics

Boehringer Ingelheim and Lilly launch diabetes education campaign

Follows the partnership’s filing of its SGLT-2 inhibitor for European approval

- PMLiVE

Allergan boosts migraine standing with $1bn acquisition

Acquires Californian neurology specialist MAP Pharmaceuticals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links